Irbesartan/Propagermanium

厄贝沙坦/丙帕诺

Report date: 2026/01/04 09:57:41

Base Information

Drug NameIrbesartan/Propagermanium
Drug Alias Name丙帕诺/厄贝沙坦Propagermanium/IrbesartanRepagermaniumDMX-200
ClassificationSmall molecules
Mechanisms of ActionAngiotensin II Receptor Type 1 antagonistsC-C chemokine receptor type 2 antagonists
TargetsAngiotensin II Receptor Type 1C-C chemokine receptor type 2
Therapy Area/IndicationsGlomerulosclerosis, Focal SegmentalDiabetic Nephropathies
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaUnited StatesTaiwan +[21] 
CombinationsYes IrbesartanPropagermanium
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesDimerix Bioscience Pty Ltd
China Registration ClassN/A

Develop Information

Active CompaniesIqvia Rds (Shanghai) Co LtdDimerix Bioscience Pty LtdAmicus Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsGlomerulosclerosis, Focal Segmental
Inactive IndicationsDiabetic Nephropathies

Other Information

ATC CodeN/A
Related LinksN/A